Skip to search formSkip to main contentSkip to account menu

bortezomib

Known as: Bortezomib [Chemical/Ingredient], N-[(1R)-1-(DIHYDROXYBORYL)-3-methylbutyl]-N-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide, [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid 
A dipeptide boronic acid analogue with antineoplastic activity. Bortezomib reversibly inhibits the 26S proteasome, a large protease complex that… 
National Institutes of Health

Related topics

Related topics

31 relations
Angiogenesis InhibitionBortezomib-Dexamethasone RegimenBortezomib/Cyclophosphamide/Dexamethasone RegimenBortezomib/Dexamethasone/Lenalidomide Regimen

Broader (1)

Antineoplastic Agents

Narrower (4)

LDP-341MLN341PS 341Velcade

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2011
Highly Cited
2011
Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial.
PURPOSE Novel agents have improved patient outcome in relapsed or relapsed/refractory multiple myeloma (MM). Preclinical data… 
Review
2011
Review
2011
Emerging therapies for the treatment of relapsed or refractory multiple myeloma
Encouraging progress has been made in the treatment of patients with relapsed/refractory multiple myeloma (MM). The rapidly… 
Review
2010
Review
2010
Proteasome inhibitors: Dozens of molecules and still counting.
Highly Cited
2009
Highly Cited
2009
Bortezomib treatment and regulatory T-cell depletion enhance the antitumor effects of adoptively infused NK cells.
Ligation of inhibitory receptors renders natural killer (NK) cells inactive against autologous tumors. Recently, the proteasome… 
Highly Cited
2007
Highly Cited
2007
Bortezomib Sensitizes Primary Human Astrocytoma Cells of WHO Grades I to IV for Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand–Induced Apoptosis
Purpose: Malignant gliomas are the most aggressive human brain tumors without any curative treatment. The antitumor effect of… 
Highly Cited
2006
Highly Cited
2006
Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity.
PURPOSE To determine the efficacy of bortezomib in patients with lymphoid malignancy, correlating clinical response with effect… 
Highly Cited
2005
Highly Cited
2005
Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma
Bortezomib, a first‐in‐class proteasome inhibitor, is active with manageable toxicities in relapsed and/or refractory myeloma. 
Highly Cited
2004
Highly Cited
2004
Proteasome inhibitor, bortezomib, potently inhibits the growth of adult T-cell leukemia cells both in vivo and in vitro
Adult T-cell leukemia (ATL) is a fatal neoplasm derived from CD4-positive T-lymphocytes, and regardless of intensive chemotherapy… 
Highly Cited
2004
Highly Cited
2004
The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor zenografts
Bortezomib (Velcade, formerly known as PS-341) is a boronic acid dipeptide derivative, which is a selective and potent inhibitor… 
Highly Cited
1967
Highly Cited
1967
Investigations of the chymotrypsin-catalyzed hydrolysis of specific substrates. 3. Determination of individual rate constants and enzyme-substrate binding constants for specific amide and ester…
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)